TuHURA Biosciences Reports $9.2 Million Net Loss for Q2 2026, Sees Increase in R&D Expenses

TuHURA Biosciences, Inc. reported a net loss of $9.2 million for the three months ended June 30, 2026, a slight improvement from the $9.5 million loss recorded in the same period of the previous year. For the six months ended June 30, 2026, the company’s net loss was $16.8 million, compared to $16.2 million for the same period in 2025. The company did not generate any revenue during these periods, maintaining its status as a clinical-stage immuno-oncology firm focused on developing novel therapeutics to combat cancer. Research and development expenses increased to $6.6 million for the second quarter of 2026, up from $4.9 million in the prior year, primarily due to ongoing clinical development of its lead product candidate, IFx-2.0, and the newly acquired TBS-2025.

In terms of financial position, TuHURA's total assets rose to $31.7 million as of June 30, 2026, compared to $27.4 million at the end of 2025. The increase was driven by a rise in cash and cash equivalents, which stood at $1.0 million, down from $3.6 million at the end of the previous fiscal year. The company’s liabilities also increased significantly, from $6.4 million at the end of 2025 to $13.2 million, largely due to the establishment of a $50 million revolving credit facility with Parkview Holdings. This facility, which carries a 12% interest rate, is intended to support the company’s operational and developmental activities.

Operationally, TuHURA has made strategic advancements, including the acquisition of Kineta, Inc. in June 2025, which brought the rights to TBS-2025 into its portfolio. The company is currently planning a Phase 1b/2 trial for TBS-2025 in patients with acute myeloid leukemia. The company’s employee headcount has also increased, reflecting its ongoing commitment to expanding its research and development capabilities. As of June 30, 2026, TuHURA had approximately 19.1 million stock options outstanding, indicating a focus on incentivizing its workforce.

Looking ahead, TuHURA anticipates continued operating losses as it advances its product candidates through clinical trials and seeks regulatory approvals. The company expects to rely on additional funding through equity offerings, debt financing, and potential collaborations to support its operations into 2028. However, management cautioned that there are no guarantees regarding the timing or success of fundraising efforts, which could impact the company’s ability to execute its development plans. The company’s accumulated deficit reached $157.9 million as of June 30, 2026, underscoring the financial challenges it faces as it works toward commercialization of its product candidates.